Potassium canrenoate
![]() | |
| Systematic (IUPAC) name | |
|---|---|
|
potassium 3-[(8R,9S,10R,13S,14S,17R)- 17-hydroxy-10,13-dimethyl-3-oxo-2,8,9, 11,12,14,15,16-octahydro-1H-cyclopenta[a] phenanthren-17-yl]propanoate | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Intravenous |
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Excretion | Renal and fecal |
| Identifiers | |
| CAS Number |
2181-04-6 |
| ATC code | C03DA02 (WHO) |
| PubChem | CID 656614 |
| DrugBank |
DB09015 |
| ChemSpider |
570975 |
| UNII |
M671F9NLEA |
| ChEMBL |
CHEMBL1371200 |
| Synonyms | SC-14266 |
| Chemical data | |
| Formula | C22H29KO4 |
| Molar mass | 396.5616 g/mol |
| |
| |
| | |
Potassium canrenoate (INN, JAN) or canrenoate potassium (USAN) (brand names Venactone, Soldactone), the potassium salt of canrenoic acid, is an aldosterone antagonist of the spirolactone group.[1] Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body. Potassium canrenoate is not licensed in the UK, but may sometimes be prescribed off-licence to treat oedema. It is given intravenously.
See also
References
- ↑ R.A. Hill; H.L.J. Makin; D.N. Kirk; G.M. Murphy (23 May 1991). Dictionary of Steroids. CRC Press. pp. 656–. ISBN 978-0-412-27060-4.
| ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Tuesday, April 05, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
